| |
|
|
Drug name
|
Condition |
Division |
| Saizen® (somatropin [rDNA origin]) |
Growth Disorders |
Accredo Nova Factor |
| Sandostatin® (octreotide acetate) |
Oncology |
Accredo Nova Factor |
| Sandostatin LAR® (octreotide/IM) |
Oncology |
Accredo Nova Factor |
| Sensipar® (cinacalcet hydrochloride) |
Hyperparathyroidism |
Accredo Nova Factor |
| Serostim® (somatropin [rDNA origin]) |
Growth Disorders |
Accredo Nova Factor |
| Simponi™ (golimumab) |
Rheumatoid Arthritis |
Accredo Nova Factor |
| Soliris™ (eculizumab) |
Paroxysmal Nocturnal Hemoglobinuria |
Accredo Nova Factor |
| Somatuline Depot® (lanreotide) |
Acromegaly |
Accredo Nova Factor |
| Somavert® |
Acromegaly |
Accredo Nova Factor |
| Sprycel® (dasatinib) |
Oncology |
Accredo Nova Factor |
| Stelara® (ustekinumab) |
Psoriasis |
Accredo Nova Factor |
| Stimate® (desmopressin acetate) |
Hemophilia/Bleeding Disorders |
Hemophilia Health Services |
| Supartz® (sodium hyaluronate) |
Osteo-arthritis |
Accredo Nova Factor |
| Supprelin LA® |
Central Precocious Puberty |
Accredo Nova Factor |
| Sutent® capsules (sunitinib malate) |
Oncology |
Accredo Nova Factor |
| Synagis® (palivizumab) |
Respiratory Syncytial Virus |
Accredo Nova Factor |
| Synvisc® (hylan G-F 20) |
Osteo-arthritis |
Accredo Nova Factor |